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Translation in Different Diagnostic
Procedures—Traditional Chinese 
Medicine and Western Medicine
Chin-Fu Hsiao,1* Hsiao-Hui Tsou,1 Yuh-Jenn Wu,2 Chien-Hsiung Lin,3 Yeu-Jhy Chang4
Recently, the modernization of traditional Chinese medicines (TCM) for treatment of patients with critical
and/or life-threatening diseases has attracted much attention in the pharmaceutical industry. However, there
exist essential differences in the evaluation of the efficacy and safety of a TCM as compared with a typical
Western medicine (WM), even though they are for the same indication. Therefore, the modernization of a
TCM should be based on a scientific evaluation of the safety and effectiveness of the TCM in terms of well-
established quantitative criteria. We propose a study design to study the calibration and validation of the
Chinese diagnostic procedure for evaluation of a TCM, with respect to a well-established clinical endpoint for
evaluation of a WM. Statistical validation of such an instrument is essential to have an accurate and reliable
clinical assessment of the performance of the TCM. Similar to the validation of a typical quality of life instru-
ment, some validation performance characteristics such as validity, reliability, and ruggedness are considered.
In this article, a design for validation of a standard quantitative instrument to be commonly employed for
diagnosis of patient function/activity, performance, disease signs and symptoms, and disease status and
severity based on Chinese diagnostic practice is proposed. Methods for statistical validation of the standard
instrument are derived. More specifically, for validation of the TCM diagnostic instrument, we consider the
following validation performance characteristics (parameters): validity (or accuracy), reliability (or precision),
and ruggedness (interrater variability). A numerical example is given to illustrate the proposed methods
for validation of the Chinese diagnostic procedure. [J Formos Med Assoc 2008;107(12 Suppl):S74–S85]
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Recently, interest in alternative and complementary
medicine has been growing in pharmaceutical
research and development. In particular, many
pharmaceutical companies have begun to focus on
the modernization of traditional Chinese medi-
cines (TCMs). With a history of over 3000 years,
TCM is a natural and holistic medical system 
encircling the entire scope of human experience.
It combines the use of Chinese herbal medicines,
acupuncture, massage, and therapeutic exercise
(e.g. Qigong, the practice of internal “air”, and
Taigie) for both treatment and prevention of dis-
ease. With its unique theories of etiology, diag-
nostic systems, and abundant historical literature,
TCM itself consists of Chinese culture and philos-
ophy, clinical practice experiences, and materials
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including usage of many medical herbs. TCM drug
treatment is typically comprised of complicated
prescriptions of a combination of a few compo-
nents. The combination is based on the Chinese
diagnostic procedure (CDP).
It should be recognized that Western and
Chinese medicine vary considerably even when
they are used for the same indication.1,2 Western
doctors will first identify the cause and nature of
disease, and treat patients accordingly, while
Chinese doctors treat patients based on so called
pattern discrimination. Experienced Chinese doc-
tors believe that all of the organs within a healthy
subject should reach the so-called global dynamic
balance or harmony. Once the global balance is
broken at certain sites such as heart, liver or kid-
ney, some signs and symptoms then appear to
reflect the imbalance at these sites. With respect
to medical practice, we tend to see the therapeutic
effect of Western medicines (WMs) faster than for
TCMs. TCMs are often considered for patients who
have chronic diseases or non-life-threatening dis-
eases. For critical and/or life-threatening diseases,
TCMs are gaining recognition as an alternative
treatment.
Furthermore, the traditional CDP for a TCM
is quite different from that of a WM. In general,
the CDP consists of four major categories, namely,
inspection, auscultation and olfaction, interroga-
tion, and pulse taking and palpation. Chinese
prescription of medicines then depends on a pat-
tern that is derived from collecting symptoms and
signs through these four diagnostic techniques.
Inspection involves observing the patient’s gen-
eral appearance (strong or weak, fat or thin), mind,
complexion (skin color), five sense organs (eye,
ear, nose, lip, tongue), secretions, and excretions.
Auscultation involves listening to the voice, ex-
pression, respiration, vomiting and coughing.
Olfaction involves smelling the breath and body
odor. Interrogation involves asking questions
about specific symptoms and the general condi-
tion including history of the present disease, past
history, personal life history, and family history.
Pulse taking and palpation can help to judge the
location and nature of a disease according to
changes in the pulse. The smallest detail can have
a strong impact on the treatment scheme as well
as on the prognosis. Each category consists of a
number of questions to collect different informa-
tion regarding patient activity/function, disease
status and/or disease severity. For example, the
CDP for stroke consists of wind syndrome (six
categories), fire–heat syndrome (nine categories),
sputum syndrome (seven categories), stasis syn-
drome (five categories), deficiency syndrome (eight
categories), and overabundant syndrome (nine
categories), while WM uses the NIH Stroke Scale
(NIHSS) developed by the US National Institute of
Neurologic Disorder and Stroke (NINDS), from
the original scale devised at the University of
Cincinnati to measure the neurologic impact of
stroke.3
The CDP is an instrument (or questionnaire)
that consists of a number of questions designed to
capture information that helps to determine the
syndrome and/or condition to be treated. As a
result, the CDP may be subjective. Consequently,
the modernization of a TCM should be based on
scientific evaluation of the efficacy and safety of
the TCM in terms of well-established clinical end-
points for a Western indication through clinical
trials on humans. When planning a clinical trial,
it is suggested that the study objectives should be
clearly stated in the study protocol. In practice,
each clinical trial must have a primary question.
At the design stage of a clinical trial, it is encour-
aged that the primary question should be care-
fully selected, clearly defined and stated in the
study protocol. Once the primary question is iden-
tified, a valid study design can be chosen and the
primary clinical endpoint can be determined ac-
cordingly. Based on the primary clinical endpoint,
sample size required for achieving a desired power
can then be calculated. For evaluating the thera-
peutic effect of a TCM, however, the commonly
used clinical endpoint is usually not applicable,
since the CDP may be subjective, as described in
the previous section. As required by most regula-
tory agencies, such a subjective instrument must
be validated before it can be used for assessment
of treatment effect in clinical trials. As a result,
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two questions may arise from the use of a CDP.
First, it is of interest to determine the accuracy
and reliability of this subjective diagnostic proce-
dure for evaluation of patients with certain dis-
eases. Second, it is also of interest to determine
how a change of an observed unit in the CDP can
be translated to a change in a well-established
clinical endpoint for a Western indication. In this
study, we addressed these two questions and pro-
posed a study design to study the calibration and
validation of the CDP for evaluation of a TCM
with respect to a well-established clinical endpoint
for evaluation of a WM. A numerical example is
given to illustrate the proposed methods.
Materials and Methods
The CDP may be subjective. Therefore, it must be
validated before it can be used for assessment of
treatment effects in clinical trials, as required by
most regulatory agencies. However, without a ref-
erence marker, not only can the CDP not be vali-
dated, but we do not know whether the TCM has
achieved a clinically significant effect at the end
of the clinical trial. Therefore, before the CDP for
evaluation of a TCM can be validated with respect
to a well-established clinical endpoint for evalu-
ation of a WM, a calibration between the scale
obtained from the CDP and the well-established
clinical endpoint is necessary. Here, we propose
a study design that allows calibration and valida-
tion of a CDP with respect to a well-established
clinical endpoint for WM (as a reference marker).
Subjects will be screened based on the criteria for
Western indications. Qualifying subjects will be
diagnosed by the CDP to establish a baseline. The
subjects will then be randomized to receive either
the test TCM or an active control (a well-established
WM). Participating physicians including Chinese
and Western clinicians will also be randomly 
assigned to either the TCM or WM arm. More
specifically, this study design will result in three
groups: Group 1—subjects who receive a WM, eval-
uated by a Chinese doctor and a Western clinician;
Group 2—subjects who receive a TCM, evaluated
by Chinese doctor A; Group 3—subjects who re-
ceive a TCM, evaluated by Chinese doctor B.
Group 1 can be used to calibrate the CDP
against the well-established clinical endpoint,
while Groups 2 and 3 can be used to validate the
CDP based on the established standard curve for
calibration. Based on the calibration model, a
detected difference by the CDP can be translated
to the well-established clinical endpoint. In addi-
tion, the CDP can also be validated against the
well-established clinical endpoint. For validation
of the TCM diagnostic instrument, we will con-
sider the following validation performance char-
acteristics (parameters): validity (or accuracy),
reliability (or precision), and ruggedness (inter-
rater variability).
Results
Calibration
Let N be the number of patients collected in
Group 1. For the data in Group 1, let xj be the mea-
surement of the well-established clinical endpoint
of the jth patient for a WM. Suppose that the TCM
diagnostic procedure consists of K items. Let zij
denote the TCM diagnostic score of the jth patient
from the ith item, i = 1, …, K, j = 1, …, N. Let yj re-
present the score of the jth patient summarized
from the K TCM diagnostic items. For simplicity,
we assume that
For the data in Group 1, let xj be the measure-
ment of the well-established clinical endpoint of
the jth patient for a WM. For TCM instrument 
calibration, we consider two situations: the mea-
surement of the well-established clinical endpoint
is normally distributed; and the measurement of
the well-established clinical endpoint is dichoto-
mous. Here, the calibration should be performed
for both baseline measurements and the mea-
surements after treatment, since the relationship
between y and x might be affected by the effect of
medication.
y zj ij
i
K
=
=1
∑ .
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The well-established clinical endpoint is
normally distributed
Based on these measurements of WM clinical end-
points (standards) and their corresponding TCM
scores, an estimated calibration curve can be ob-
tained by fitting an appropriate statistical model
between these standards and their corresponding
TCM scores. The estimated calibration curve is also
known as the standard curve. In a similar manner
to that of calibration of an analytical method,4,5
we will consider the following four candidate
models:
• Model 1: yj = a + bxj + ej,
• Model 2: yj = bxj + ej,
• Model 3: yj = axjβej,
• Model 4: yj = a ej,
where a and b are unknown parameters and 
the e values are independent random errors with
E(ej) = 0 and finite Var(ej) in Models 1 and 2, and
E(log(ej)) = 0 and finite Var(log(ej)) in Models 3
and 4.
Model 1 represents a simple linear regression
model which is the most commonly used statis-
tical model for establishment of standard curves
for calibration. Model 1 reduces to Model 2 when
the standard curve passes through the origin.
Models 3 and 4 are useful when there is a non-
linear relationship between y and x. It should be
noted that both Models 3 and 4 are in fact equiv-
alent to a simple linear regression model after
logarithmic transformation. For a given data set
observed from Group 1, the standard curve under
each model can be obtained by estimating the cor-
responding parameters through the least squares
method. The standard curve is then used to eval-
uate the unknown WM clinical endpoint x0 for a
given TCM score y0. The unknown WM clinical
endpoint is determined by solving x based on
the standard curve, which assumes the parameter
estimates are the true values of the parameters.
The well-established clinical endpoint
is dichotomous
Suppose the measurement of the well-established
clinical endpoint is either x = 0 or x = 1. In other
words, x can be thought of as a classification 
variable defining groups of observations. For the
calibration of the TCM diagnostic procedure, we
can develop a discriminant criterion to classify
each observation into one of the two groups
(x = 0 or x = 1) based on the K TCM diagnostic
items. Let zj = (z1j, …, zKj)’ be the K TCM diagnos-
tic score of jth patient. Assume that zj for each
group has a multivariate normal distribution.
Based on the observed results from Group 1, 
we can derive the posterior probability of zj
belonging to group x, p(x | zj). The derivation of
p(x | zj) is given in Appendix I. Consequently, an 
observation zj is classified into group x if
When no assumptions can be made about the
distribution within each group, or when the dis-
tribution is assumed not to be multivariate, non-
parametric methods can be used to estimate the
group-specific densities.6,7
Validity
For the sake of convenience, we assume that the
well-established clinical endpoint is normally
distributed. For the validity of a TCM instrument,
we can evaluate the bias of the TCM instrument.
That is, we are concerned about the accuracy of
the TCM instrument, i.e. whether the questions in
the TCM instrument are the right questions to cap-
ture the information regarding patient activity/
function, disease status, and disease severity. We
will use Group 2 to validate the CDP based on
the previously established standard curve for cali-
bration from Group 1. Let X be the unobservable
measurement of the well-established clinical end-
point for WMs, which can be quantified by the
TCM items, Zi, i = 1, …, K, based on the estimated
standard curve in the previous section. Since both
Models 3 and 4 can be transformed into a linear
model using a log-transformation, for convention,
we simply choose a linear model to illustrate the
proposed methods for validation of the CDP.
That is, we consider that
X = (Y − a)/b,
p x p uj u j( | ) max ( | ).,z z= = 0 1
e xjβ
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where That is, Model 1 was used for
calibration. Suppose that X is distributed as a
normal distribution with mean q and variance τ2.
Let Z = (Z1, …, ZK)’. Again, suppose Z follows 
a distribution with mean m = (m1, …, mK)’ and
variance Σ. To assess the validity, it is desired to
see whether the mean of Zi, i = 1, …, K is close to 
(a+bq)/K. Let Then 
Consequently, we can claim that the instrument
is validated in terms of its validity if
(1)
for some small prespecified d. More specifically, to
verify (1), it is desired to test the null hypothesis
for at least one i. (2)
To apply the approach of two one-sided tests, for
each i, we will construct a (1 − α)100% confidence
interval, (hi-, hi+), for . The construction for
(hi -, hi +) is given in Appendix II. For each fixed i,
a size a test based on the two one-sided tests ap-
proach rejects the hypothesis that if and
only if (hi−, hi +) is within (−d, d). Then, using the
approach of intersection−union, a size a test re-
jects the null hypothesis (2) and concludes that
the TCM instruments are validated if and only if
(hi−, hi +) is within (−d, d) for all i.
Reliability
The calibrated well-established clinical endpoints
derived from the estimated standard curve are
considered reliable if the variance of X is small.
We can now test the hypothesis
H0: t2 ≥  vs. HA: t2 < , (3)
for some fixed  to verify the reliability of 
estimating q by X. We will use Group 2 to verify
the reliability based on the previously estab-
lished standard curve for calibration. According
to Lehmann,8 we can construct a (1 − α)100% one-
sided confidence interval for τ2, say (0, x). The
calculation of x is given in Appendix III. Con-
sequently, we can reject the null hypothesis (3)
and conclude that the items are reliable in esti-
mation of q if x < .
Ruggedness
An experienced Chinese doctor usually prescribes
a TCM based on the combined information ob-
tained from the four major categories and his/
her best judgment. In practice, the diagnostic
procedure for a TCM can vary from one Chinese
doctor to another. Although it may reduce within-
patient variability, it can increase the between-rater
variability, which can significantly bias the evalu-
ation of the efficacy and safety of the TCM under
study. Therefore, an acceptable TCM diagnostic
instrument should produce similar results for dif-
ferent raters. In other words, it is desirable to
quantify the variation caused by rater and the pro-
portion of interrater variation to the total variation.
We will use the one-way random model to evalu-
ate instrument ruggedness.4 A model describing
a one-way random model is
xij = n + Ai + eij, i = 1 (Group 2), 2 (Group 3);
j = 1, …, N,
where xij is the calibrated well-established clinical
endpoint of the jth patient obtained from the ith
rater derived from the estimated standard curve,
n is the overall mean, Ai denotes the effect of the
ith rater and is assumed to be distributed i.i.d.
N(0, ), and eij denotes the random error of the jth
patient’s scale derived from the ith rater, which is
assumed to be distributed i.i.d. N(0, ). It is also
assumed that Ai and eij are independent variables.9
To show that the interrater variability is within
an acceptable limit w, we can test the hypothesis
H0: ≥ ω vs. H1: < ω. (4)
Since there exists no exact (1 − α)100% confidence
interval for , we can then derive the Williams–
Tukey interval,10 (LA, UA), with a confidence level
between (1 − 2α)100% and (1 − α)100% for .
The derivation of (LA, UA) is shown in Appendix
IV. Accordingly, the null hypothesis (4) is rejected
at the a level of significance if UA < ω.
Numerical example
To illustrate the methods proposed, a random-
ized trial was conducted to study the effect of
acupuncture on stroke patients. Patients with an
acute ischemic stroke between 4 and 10 days were
s A
2
s A
2
s A
2s A
2
s A
2
s A
2
| |m mi − ≥d
m mi −
H m m d0 :| |i − ≥  
| | , ,..., ,m m di i K− < ∀ = 1
q m a b= −( )/ .m m=
=
1
1K ii
K∑ .
Y Zi
i
K
=
=1
∑ .
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allocated into three groups. The diagnostic criteria
of acute ischemic stroke consisted of the typical
presentations of acute onset of focal neurologic
deficits, and excluded other possible organic brain
lesions by brain computed tomography and/or
magnetic resonance imaging. Thirty stroke patients
received aspirin 100 mg/day and were evaluated by
a Chinese doctor and a Western clinician (Group
1), 30 stroke patients received acupuncture and were
evaluated by Chinese doctor A (Group 2), and
30 stroke patients received acupuncture and were
evaluated by Chinese doctor B (Group 3). The com-
bination of scalp and body acupoints that fit the
Chinese traditional theory was applied in patients
from Groups 2 and 3. The measurement that the
Western clinician used was the NIHSS, whereas
the TCM diagnostic instruments considered in
this study were wind and fire–heat syndromes.
More specifically, patients in Group 2 had both
NIHSS and TCM scores, while patients in Groups
2 and 3 had only TCM scores. Outcome assess-
ments were recorded at randomization, 14 days, 1
month, 3 months, and 6 months after treatment.
The TCM instruments are summarized based
on the rating scales of the wind and fire–heat
syndromes shown in Table 1, that is, K = 2. More
specifically, the wind syndrome is a rating scale
with six categories, including onset conditions
(0–8), limb condition (0–7), tongue body (0–7),
eyeball condition (0–3), string-like pulse (0–3),
and head condition (0–2). Patients with a total
score > 7 were considered to have wind syndrome.
On the other hand, the fire–heat syndrome con-
sists of nine categories, including tongue condi-
tion (0–6), tongue fur (0–5), stools (0–4), spirit
(0–4), facial and breath conditions (0–3), fever
(0–3), pulse (0–2), mouth (0–2), and urine (0–1).
Again, patients with a total score > 7 were consid-
ered to have fire–heat syndrome. In both syn-
dromes, the larger the scale, the more severe the
syndrome. Data are shown in Tables 2 and 3.
Let y represent the sum of the scores of wind
and fire–heat syndromes and x represent the NIH
stroke score. Here, we used the baseline measure-
ments for calibration. From Group 1, the estimated
standard curve based on Model 1 was given as
y = 7.092 + 1.820x. The estimated regression line
and the original data are presented in the Figure.
Group 2 was used to validate the CDP based
on the previously established standard curve. We
claimed that the instruments of wind and
fire–heat syndromes were validated if
for some small prespecified d. It can be seen from
Group 2 that = 9.733 and = 7.067.
Accordingly, (h1−, h1 +) and (h2−, h2 +) were re-
spectively given by (0.328, 2.338) and 
(−2.338, −0.328). In this case, we could reject the
null hypothesis (2) if d = 3.
We also used Group 2 to evaluate the reliabil-
ity of the items for the TCM instrument. That is,
the wind and fire–heat syndromes for the TCM
instrument were considered reliable if the vari-
ance of X derived from the previously established
2mˆ1mˆ
| | , , ,m m di i− < ∀ = 1 2 
Table 1. Wind and fire–heat syndromes
Wind syndrome Fire–heat syndrome
Category Score Category Score
Onset conditions 0–8 Tongue conditions 0–6
Limb conditions 0–7 Tongue fur 0–5
Tongue body 0–7 Stool 0–4
Eyeball conditions 0–3 Spirit 0–4
String-like pulse 0–3 Facial and breath conditions 0–3
Head conditions 0–2 Fever 0–3
Pulse 0–2
Mouth 0–2
Urine 0–2
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standard curve was small. Assume that  = 15.
From Group 2, a 95% one-sided confidence inter-
val for τ2 was (0, 13.48). Since 13.48 is < 15, we
could reject the null hypothesis (3) at the 5%
level of significance, and conclude that the TCM
instrument was validated in terms of its preci-
sion. Selection of  should reflect the consider-
able information that existed in previous studies.
It may also vary from disease to disease.
Groups 2 and 3 were used to quantify the vari-
ation caused by raters. The response variable was
logarithmically transformed to normalize their
distributions. The ANOVA is given in Table 4,
which shows that SSA = 0.012 and SSE = 13.813.
Hence, estimates for and s 2 were given by
and . Since F= 0.05 with a p value
of 0.8262, we could not reject the null hypothesis
H0: = 0 at the 5% level of significance. The
Williams–Tukey interval with a confidence level
between 90% and 95% for was given by (0,
0.399). This suggests that the interrater variation
was not significant.
Discussion
Although the modernization of TCM for treatment
of patients with critical and/or life-threatening
diseases has attracted much attention in the phar-
maceutical industry, it should be recognized that
there are fundamental differences in the scientific
evaluation of the efficacy and safety of a TCM as
compared with a typical WM. The validation of a
standard quantitative instrument in a TCM clinical
trial plays an important role in providing an ac-
curate and reliable assessment of the safety and
effectiveness of the TCM under investigation. Most
importantly, the calibration of the quantitative
instrument with respect to a well-established
clinical endpoint provides clinicians with a better
understanding of whether the observed significant
difference from the quantitative instrument is clin-
ically meaningful. It should be noted that only a
well-calibrated and validated quantitative instru-
ment is able to lead to accurate estimation of the
sample size required for achieving a desired power
for detecting a clinically meaningful difference.
In this study, four common statistical models
were used for the calibration of the CDP with re-
spect to a well-established clinical endpoint. How-
ever, the relationship between the CDP and the
well-established WM clinical endpoint may vary
considerably from disease to disease. For some
diseases, the relationship might be linear. In some
cases, a generalized linear model may be more su-
itable for the relationship between CDP and WM.
Therefore, intensive research in the design and
analysis method might be needed to correctly 
interpret the relationship between the CDP and
WM. If the relationship between the TCM score
s A
2
s A
2
sˆ A
2 0=sˆ 2 =0.012
s A
2
Table 2. Data for Group 1
Subject ID
TCM score NIH stroke 
(Wind + Fire–heat) score
1 19 6
2 11 2
3 8 2
4 10 2
5 16 4
6 19 8
7 22 9
8 10 2
9 18 4
10 15 6
11 21 8
12 13 5
13 23 8
14 26 10
15 13 5
16 32 13
17 17 5
18 18 6
19 11 3
20 23 7
21 12 2
22 27 11
23 12 2
24 22 8
25 17 5
26 13 3
27 13 5
28 31 13
29 15 4
30 17 3
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Table 3. Data for Groups 2 and 3
Group 2 subject ID Wind Fire–heat Group 3 subject ID Wind Fire–heat
1 8 3 1 11 3
2 17 6 2 11 8
3 7 10 3 11 8
4 11 0 4 11 4
5 7 3 5 9 5
6 7 13 6 5 11
7 9 3 7 12 3
8 18 4 8 13 3
9 12 10 9 13 6
10 13 9 10 10 5
11 7 3 11 11 7
12 13 10 12 8 7
13 15 6 13 7 6
14 7 16 14 8 5
15 9 11 15 9 4
16 11 12 16 8 7
17 5 7 17 11 6
18 5 16 18 17 1
19 5 6 19 13 4
20 11 0 20 8 3
21 12 0 21 13 3
22 5 8 22 7 8
23 12 0 23 11 6
24 12 10 24 7 6
25 9 4 25 12 3
26 7 6 26 8 9
27 7 3 27 7 9
28 14 8 28 11 7
29 8 12 29 10 5
30 9 13 30 13 4
2
10
20
30
4 6 8 10 12 14
NIH stroke score
TC
M
 s
co
re
TCM = 7.09 + 1.82 × NIH
R2 = 0.8961
Figure. Scatter plot of sum of wind syndrome score and fire–heat syndrome score versus NIH stroke score for the data
in Group 1, and the estimated standard curve.
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and the WM endpoint is not one of the four can-
didate models, more complicated calibration
functions or transformations may be required.
Note that in the example, we used the baseline
measurements for calibration to illustrate our
approach. However, it is strongly suggested that
the calibration should be performed for baseline
measurements and those after treatment, since
the relationship between y and x might be affected
by the effects of a medication. Also note that when
larger variation caused by raters occurs, two ques-
tions may arise. First, the CDP instrument may be
defective. Second, TCM doctors might have dif-
ferent TCM practices or experiences. For the for-
mer case, the CDP instrument needs to be refined.
For the latter case, the rater should revisit the es-
tablished Chinese diagnostic criteria in order to
ensure that consistency is maintained.
We tend to believe that TCMs are mostly made
of natural herbs, and thus are nearly free from side
effects and much less toxic than Western drugs.
However, scientific documentation regarding clin-
ical evidence of safety and efficacy of these TCMs
remain limited. Although the use of TCM in hu-
mans has a history of more than 3000 years, there
have been no regulatory requirements with regard
to the assessment of safety and effectiveness of
TCMs until recently. However, the regulatory au-
thorities of both China and Taiwan have now
published guidelines for clinical development of
TCMs.11–13 In addition, the United States Food and
Drug Administration has also published guidance
for botanical drug products.14 These regulatory re-
quirements for TCM research and development,
especially for clinical development, are very similar
to the well-established guidelines for pharma-
ceutical research and development for WMs. It is
unclear whether these regulatory requirements are
feasible for the research and development of TCM
given that there are so many fundamental differ-
ences in medical practice, drug administration and
diagnostic procedures. Consequently, it is strongly
suggested that current regulatory requirements
should be modified to reflect these fundamental
differences.
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Table 4. Analysis of variance table for data in Groups 2 and 3
Source of variation Degrees of freedom Sum of squares Mean square F p
Rater 1 0.012 0.012 0.05 0.8262
Error 58 13.813 0.238
Total 59 13.825
Translation in different diagnostic procedures
J Formos Med Assoc | 2008 • Vol 107 • No 12 Suppl S83
Appendix I
Let mx be the K-dimensional vector containing score means in group x. Let Sx and Sp denote the covari-
ance matrix within group x and the pooled covariance matrix respectively. The squared Mahalanobis
distance from zj to group x can be expressed as
where Vx can be chosen as Sx or Sp. Accordingly, the group-specific density estimate at zj from group x is
given by
fx(zj) = (2π)–K/2|Vx|−1/2exp(−0.5dx2(zj)).
Let qx be the prior probability of membership in group x. By applying Bayes’ theorem, the posterior
probability of zj to group x is given by
where the summation is over both groups. The generalized square distance from z to group x can be
defined as
where
and
where |Sx| is defined as the determinant of Sx. As a result, the posterior probability of zj belonging to
group x is equal to
Appendix II
We can write
where , , and
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Assume that the TCM instrument is administered to N patients from Group 2. Let
Consequently, we can derive that
where t1 − α; N - 1 is the (1 − α)th quantile of the t-distribution with N − 1 degrees of freedom.
Appendix III
Based on the estimated standard curve, we can derive that
Note that the sample distribution of
has a c2 distribution with N − 1 degrees of freedom. According to Lehmann,8 we can construct a 
(1 − α)100% one-sided confidence interval for t 2 as follows
Appendix IV
Two sums of squares are the sum of squares within, SSE, and the sum of squares between, SSA. That is,
and
where and . Let MSA and MSE denote mean squares for 
factor A and mean square error. Then MSA = SSA and MSE = SSE/[2(N − 1)]. As a result, the analysis of
variance estimators of s2 and can be obtained as follows:
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and
.
Consequently, the Williams–Tukey interval,10 (LA, UA), with a confidence level between (1 − 2α)100%
and (1 − α)100% for can be expressed as
and
where FL = F(1 − 0.5α, 1, 2(N − 1)) and FU = F(0.5α, 1, 2(N − 1)) represent the (1 − 0.5α)th and (0.5α)th
upper quantiles of a central F distribution with 1 and 2(N − 1) degrees of freedom,
are the (1 − 0.5α)th and (0.5α)th upper quantiles of 
a central c2 distribution with 1 degree of freedom, and FA = MSA/MSE.
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